siRNA vs. ASOs
Oct 16, 2026
siRNA vs. Antisense Oligonucleotides: Which RNA Technology Has Greater Commercial Potential?
Summary siRNA and ASOs are emerging as major RNA-based therapeutic platforms, enabling targeted disease treatment by silencing or modulating gene expression. siRNA holds a commercial advantage in revenue generation and dosing convenience. Marketed siRNA drugs generated approximately $4.2 billion in disclosed...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
